MedTrace Logo

Safety and Efficacy Evaluation of Decitabine With R-GDP

NCT03535753 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-05-24

No results posted yet for this study

Summary

Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients

Conditions

  • NHL

Interventions

DRUG

Decitabine and R-GDP

Decitabine and R-GDP

Sponsors & Collaborators

  • Beijing Immunochina Medical Science & Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongmei Jing, MD · Peking University Third Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-09-01
Completion
2020-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03535753 on ClinicalTrials.gov